^
    1d
    Oracle: Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL (clinicaltrials.gov)
    P3, N=86, Completed, The Lymphoma Academic Research Organisation | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025
    Trial completion • Trial completion date
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • MME (Membrane Metalloendopeptidase)
    |
    gemcitabine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)
    1d
    SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions. (PubMed, Clin Lymphoma Myeloma Leuk)
    Brentuximab vedotin-based regimens have reshaped frontline therapy for CD30-positive disease, while ongoing studies are exploring the role of novel therapies including epigenetic modulators, phosphatidylinositol 3-kinase (PI3K) and JAK inhibitors, and immune-based therapies across the PTCL spectrum. Future progress will depend on biomarker-driven clinical trials, refined patient selection, and the incorporation of genomic and immune signatures to personalize therapy.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive
    |
    Adcetris (brentuximab vedotin)
    1d
    The interaction between Marek's disease virus pUL11 and pUL56 antagonizes STING-mediated IFN-β production in cultured chicken cells. (PubMed, Biochem Biophys Res Commun)
    Furthermore, the induction of chicken IFN-β with a STING agonist was significantly impaired in the context of MDV pUL11 and pUL56 co-expression. This study highlights the broader conservation of interacting partners across cognate herpesviruses, and provides the evidence that MDV pUL11 and pUL56 collaborate to counteract innate immune signaling.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1) • IFNB1 (Interferon Beta 1)
    1d
    Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma. (PubMed, J Clin Oncol)
    The PRIMO study demonstrates significant activity and tolerability of duvelisib in patients with R/R PTCL, most notably in the AITL subgroup. This provides strong rationale for further development in PTCL, and more specifically in the subgroup of nodal T-follicular helper cell lymphoma.
    P2 data • Journal
    |
    PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
    |
    Copiktra (duvelisib)
    1d
    SGN35C-001: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Apr 2029 --> Apr 2026 | Trial primary completion date: Apr 2028 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    PF-08046044
    1d
    Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD33 (CD33 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    bendamustine • Folotyn (pralatrexate)
    1d
    STP938-101: A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas (clinicaltrials.gov)
    P1/2, N=180, Recruiting, Step Pharma, SAS | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    dencatistat (STP938)
    2d
    A prospective, single-center Phase I/II clinical study of golixitinib in combination with chidamide in systemic treated cutaneous T-cell lymphoma (ChiCTR2600120648)
    P=N/A, N=65, Recruiting, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
    New trial
    |
    Xospata (gilteritinib) • Epidaza (chidamide)
    2d
    A single-arm, open-label, multicenter exploratory clinical trial of brentuximab vedotin combined with chidamide for the treatment of CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL) patients (ChiCTR2600119766)
    P=N/A, N=33, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Adcetris (brentuximab vedotin) • Epidaza (chidamide)
    3d
    Diffuse CD30-Positive Cutaneous Infiltrate in a Clinically Suspected Hidradenitis Suppurativa Lesion: Histopathologic and Diagnostic Challenges. (PubMed, J Cutan Pathol)
    Early biopsy, immunophenotypic analysis, and clinicopathologic correlation are essential to guide appropriate management in atypical or treatment-resistant lesions. Rather than demonstrating a novel association with HS, this report emphasizes diagnostic and classification challenges at the interface between primary cutaneous and systemic ALCL, which are of direct relevance to cutaneous pathologists.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
    |
    TNFRSF8 positive • TNFRSF8 expression
    3d
    Cutaneous Manifestation of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma: A Clue to A Gastrointestinal Malignancy. (PubMed, J Cutan Pathol)
    Cutaneous involvement in MEITL is exceedingly uncommon, and this case underscores the importance of including MEITL in the differential diagnosis of skin biopsies of mostly dermal-based lymphomas with only slight epidermotropism with a CD8+/CD56+/TCRδ-/EBER- phenotype. Early endoscopic evaluation may facilitate diagnosis of occult intestinal disease.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1)